Could hormones explain Women's higher Alzheimer's risk?

NCT ID NCT03821857

Recruiting now Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how ovarian hormones might influence aging and Alzheimer's disease in women aged 60 and older. Researchers will use special PET scans to measure brain changes related to Alzheimer's. The goal is to better understand why women are more likely to develop the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help explain why women are at higher risk for Alzheimer's and guide future prevention strategies.
What could go wrong: This is an observational imaging study, not a treatment trial. It may not lead to direct benefits for participants or produce clear answers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic
ENROLLING_BY_INVITATION

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.